Antifibrinolytic drugs are also known as fibrinolytic inhibitors. They are primarily used for preventing the fibrinolysis or lysis of blood clots. The fibrinolysis is basically a process which is stimulated plasminogen used for removing the excess fibrin. Moreover, they are used for controlling the massive hemorrhage and for other coagulation disorders. The hemophilia, antifibrinolytic agents consisting of tranexamic acid or epsilon aminocaproic acid are generally used for oral bleeding or the dental surgery. Some of the most common antifibrinolytic drugs such as tranexamic acid and ε-aminocaproic acid, and the serine protease inhibitor, aprotinin and others.
According to study, “Antifibrinolytic Drugs Market by Indication (Gynecology, Hereditary Angiedema, Fibrinolytic Response Testing, Surgeries, and Others) and End user (Hospitals & Clinics, Ambulatory Surgical Centers, and Healthcare Specialty Process): Global Opportunity Analysis and Industry Forecast, 2019-2026”. Some of the key companies that are currently working in the global Antifibrinolytic drugs market are Acic Fine Chems, Aurobindo Pharma Ltd., Zydus Cadila, Xanodyne Pharmaceuticals, Akorn, Mylan, Pfizer (GenMed), Amerigen Pharms Ltd, Sanofi, and Takeda.
Based on indications, antifibrinolytic drugs market is segmented into gynecology, fibrinolytic response testing, hereditary angiedema, surgeries, and others. Gynecology includes menorrhagia, gynecological surgery, pregnancy, haemorrhage, parturition, bleeding disorders, Gastrointestinal (GI) bleeding and dental surgery. Gynecology segment holds major share in market and is expected to exhibit a prominent growth rate in the near future, due to rise in adoption of these drugs to prevent menorrhagia i.e. heavy menstrual flow. Surgeries include cardiac surgery, liver surgery, orthopedic surgery and neurosurgery. Based on drug type, market is segmented into Amicar, Tranexamic acid injection, Aminocaproic acid, Tranexamic acid oral, Aprotinin, RiaSTAP, Cyklokapron, Trasylol and Lysteda. In addition, based on end-user, market is segmented into hospitals, healthcare specialty processes, ambulatory surgical centers, clinics and others. Hospital segment dominates the market owing to increase in usage of these drugs in hospitals as most of the surgeries such as neurosurgeries and cardiovascular are performed in hospitals.
The antifibrinolytic drugs market is driven by significant increase in surgical procedures, followed by surge in severe road accidents, growth in high-risk geriatric population, surge in incidence of angioedema and growth in healthcare investments. However, high cost of these drugs may impact the market. Moreover, increase in research & development (R&D) for developing novel innovative antifibrinolytic drugs is a key opportunity for market.
Based on geography, the North-American is the dominating region in the antifibrinolytic drugs market owing to broad technical applications of antifibrinolytic drugs, increase in strict rules at the work place and rise in awareness about these drugs in the region. Whereas, the European and Asian-Pacific regions are estimated to witness higher growth rate due to high disposable income, mandatory medical insurance and high research & development in the health care sector over the forecast period. In upcoming years, it is estimated that future of the market will be bright as a result of considerable surge in prevalence of bleeding disorders during the forecast period. The global antifibrinolytic drugs market was valued at US $13,593 million in 2018 and is anticipated to reach US $19,333 million by 2026, registering a CAGR of 4.5% from 2019-2026.
For More Information, Click on the Link Below:-
Ankur Gupta, Head Marketing & Communications